Alligator Bioscience AB’s Post

Great way to start a Monday – by sharing that we’ve once again been recognized on Allbright’s Green List! 🌿 AllBright has just released their annual review of gender equality among Swedish publicly listed companies. And Alligator Bioscience AB has earned a spot on the Green List by achieving a balanced gender representation (40/60) in our leadership team. We’re committed to fostering an inclusive environment, and this recognition reinforces our sustainability efforts to maintain diversity and equality at all levels of our organization. 🐊 A big thanks to Allbright for your continued work in highlighting the importance of representation in corporate leadership! ⭐ To read today's report, just follow this link: 👉 https://lnkd.in/dgftyhkP

📢 Psst! We are thrilled to announce that positive interim data from the Phase 1 trial of our bispecific antibody, ALG.APV-527, co-developed with Aptevo Therapeutics Inc will be presented at the European Society for Medical Oncology (ESMO) Annual Congress 2024. 📅 Presentation Date: Saturday, September 14, 2024 🏢 Location: Barcelona, Spain 📝 Poster Number: #668P 👨⚕️ Presenter: Dr. Thomas Marron, MD, PhD Stay tuned for more updates from #ESMO2024!

👉 Check out today's BioStock interview with the new Alligator Bioscience AB – CFO Johan Gileus! 🐊

Alligator Bioscience Q2 2024 Earnings Call Alligator Bioscience will host a livestream (in English) for investors, analysts and media on Thursday, July 11, 2024, at 4:15 PM CEST/10:15 AM EDT. Alligator will publish its Q2 report on Thursday, July 11, 2024, at 8:00 AM CEST.

Psst! Out today - Alligator Bioscience AB's half-year report for 2024! Check out the corresponding PR: https://lnkd.in/dJg_85BH and don't miss our conference call today, at 4:15 pm CEST, over on our Youtube channel, where CEO Søren Bregenholt, CFO Marie Svensson and CMO Dr Sumeet Ambarkhane, MD will present and comment on the report. 👉 https://lnkd.in/dhEpyD2G

Pssst! 🐊 Don't miss today's BioStock - Connecting Innovation and Capital piece on Alligator Bioscience AB, with CEO Søren Bregenholt commenting on the latest #OPTIMIZE1 data. Follow the post link... 👉

🌟 SUBSTANTIAL OVERALL SURVIVAL BENEFIT AND UNPRECEDENTED DURATION OF RESPONSE! 🌟 Today we’re both proud and excited to announce the results from the 18-month follow-up analysis of #OPTIMIZE1, Alligator’s Phase 2 trial with #mitazalimab in first-line #pancreaticcancer. For an answer to the natural question, “Why?”, let us just start with: ·     Median Overall Survival increased to 14.9 months and survival rate at 18 months was 36.2%, nearly twice as high as the 18.6% previously reported for FOLFIRINOX ·     Further deepening of tumor shrinkage was evident with additional objective responses over long treatment duration ·     Results demonstrate an unprecedented median Duration of Response of 12.6 months and confirm immunotherapeutic contribution of mitazalimab when added to chemotherapy ·     With a median 18-month follow-up duration, these results from the ongoing OPTIMIZE-1 trial validate and strengthen mitazalimab’s previously reported robust clinical benefit As CEO Søren Bregenholt puts it: “These latest results from the OPTIMIZE-1 study of our lead asset provide a strong validation of the clear and sustained clinical benefit produced by mitazalimab when combined with mFOLFIRINOX in the treatment of first-line pancreatic cancer. In fact, mitazalimab increases your chance of being alive at the 18-month mark by 95 percent, compared to published FOLFIRINOX data. These highly promising outcomes warrant continued clinical development of mitazalimab in a confirmatory setting and we are committed to bringing mitazalimab to pancreatic cancer patients as fast as possible.” For the full PR, just follow this link. 👉 https://lnkd.in/dVgcV5Fr

Excited to share that positive Phase 2 results from our #OPTIMIZE1 trial with #mitazalimab will be presented at #ESMOGI24! 🎉 This marks another milestone, building on the recent Alligator Bioscience AB's presentations at ASCO and the publication in The Lancet Oncology. Details of the upcoming presentation: 📄 CD40 agonist mitazalimab combined with mFOLFIRINOX in patients with metastatic pancreatic ductal adenocarcinoma: A primary analysis of the OPTIMIZE-1 phase 1b/2 study 🎤 Type: Oral Presentation ⏰ Time: Saturday, June 29, 8:45 AM CET 📍 Location: Room 13a 👤 Presenter: Prof. Teresa Macarulla Mercade, MD, PhD, Vall d’Hebron, Barcelona Mitazalimab’s potential to improve treatment outcomes is a beacon of hope for patients and families affected by mPDAC. Join us to learn more about this groundbreaking research. Follow the post link to read today’s press release! 🐊

📢 Thrilled to announce that Johan Gileus will join Alligator Bioscience AB as CFO starting August 12, 2024. With over 25 years of financial leadership, Johan brings a wealth of experience from overseeing significant projects such as Phase 3 clinical trials and outlicensing in Japan. Join us in welcoming Johan to the Alligator family. His expertise will undoubtedly be invaluable as we forge ahead in our mission to develop groundbreaking treatments for hard-to-treat cancers. 🐊 Want to read more? Follow the post link. 👉